Global Markets for Neglected Tropical Disease Treatments

Chapter 1: Introduction

Study Goals and Objectives

Reasons for Doing this Study

Scope of Report

Information Sources

Methodology

Geographic Breakdown

Analyst’s Credentials

Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Disease Overview

Malaria

Incidence and Geographical Distribution

Etiology and Symptoms

Socioeconomic Burden

Current Method of Treatment

Leishmaniasis

Incidence and Geographical Distribution

Etiology and Symptoms

Socioeconomic Burden

Current Method of Treatment

Schistosomiasis

Incidence and Geographical Distribution

Etiology and Symptoms

Socioeconomic Burden

Current Method of Treatment

Lymphatic Filariasis

Incidence and Geographical Distribution

Etiology and Symptoms

Socioeconomic Burden

Current Method of Treatment

Chagas Disease

Incidence and Geographical Distribution

Etiology and Symptoms

Socioeconomic Burden

Current Method of Treatment

African Trypanosomiasis

Incidence and Geographical Distribution

Etiology and Symptoms

Socioeconomic Burden

Current Method of Treatment

Dengue

Incidence and Geographical Distribution

Etiology and Symptoms

Socioeconomic Burden

Current Method of Treatment

Ebola

Incidence and Geographical Distribution

Etiology and Symptoms

Socioeconomic Burden

Current Method of Treatment

Zika

Incidence and Geographical Distribution

Etiology and Symptoms

Socioeconomic Burden

Current Method of Treatment

Chapter 4: Market Overview

Total Addressable Market

Malaria

Malaria – Market Share by Geography

Leishmaniasis

Leishmaniasis – Market Share by Geography

Schistosomiasis

Schistosomiasis – Market Share by Geography

Lymphatic Filariasis

Lymphatic Filariasis – Market Share by Geography

Chagas Disease

Chagas Disease – Market Share by Geography

African Trypanosomiasis

Dengue

Dengue – Market Share by Geography

Ebola

Zika

Zika – Market Share by Geography

Donations by Pharmaceutical Companies: Access to Medicines

Chapter 5: Market Influencing Factors

Market Drivers

Malaria

Leishmaniasis

Lymphatic Filariasis

Chagas Disease

African Trypanosomiasis

Dengue

Ebola

Zika

Market Deterrents

Malaria

Leishmaniasis

Schistosomiasis

Lymphatic Filariasis

Chagas Disease

African Trypanosomiasis

Dengue

Ebola

Zika

Unmet Needs

Malaria

Leishmaniasis

Schistosomiasis

Lymphatic Filariasis

Chagas Disease

African Trypanosomiasis

Dengue

Ebola

Zika

Chapter 6: Research and Development

Malaria

Clinical Trials in Malaria

Leishmaniasis

Clinical Trials in Leishmaniasis

Schistosomiasis

Clinical Trials in Schistosomiasis

Lymphatic Filariasis

Clinical Trials in Lymphatic Filariasis

Chagas Disease

Clinical Trials in Chagas Disease

African Trypanosomiasis

Clinical Trials in African Trypanosomiasis

Dengue

Clinical Trials in Dengue

Ebola

Clinical Trials in Ebola

Zika

Clinical Trials in Zika

Chapter 7: Patent Review

Malaria

Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

Leishmaniasis

Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

Schistosomiasis

Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

Lymphatic Filariasis

Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

Chagas Disease

Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

African Trypanosomiasis

Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

Dengue

Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

Ebola

Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

Zika

Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

Chapter 8: Company Profiles

Appendix: Abbreviations

About BCC Research

About BCC Research

BCC Library Access

BCC Custom Research

List of Tables

Summary Table: Global Market for Neglected Tropical Diseases, by Indication, Through 2021 ($ Millions)

Table 1 Key Trends in Neglected Tropical Diseases

Table 2 Estimated Malaria Incidence (per 1,000 at Risk), 2000-2015

Table 3 Suspected Malaria Cases, 2010-2015 (Millions)

Table 4 Confirmed Malaria Cases, 2010-2015 (Millions)

Table 5 Estimated Spending on Malaria Treatment in Sub-Saharan Africa, 2010-2014 ($ Millions)

Table 6 WHO Guidelines for Treatment of Malaria

Table 7 Number of Cases of CL in Select High Burden Countries, 2010-2014

Table 8 Number of Cases of VL in Select High Burden Countries, 2010-2014

Table 9 Incidence of CL and VL in High Burden Countries, 2014 (Cases per 10,000 Inhabitants in Endemic Areas)

Table 10 Global Disease Burden of Leishmaniasis, 2015

Table 11 WHO Guidelines for Treatment of Leishmaniasis

Table 12 Number of People Treated Globally, 2010-2014 (Millions)

Table 13 Global Disease Burden of Schistosomiasis, 2015 (Years)

Table 14 Global Disease Burden of Lymphatic Filariasis, 2015 (Years)

Table 15 Prevalence and Incidence (Number) of Chagas Disease, 2015

Table 16 Global Disease Burden of Chagas Disease, 2015 (Years)

Table 17 Prevalence and Incidence (Number) of Chagas Disease, 2015

Table 18 Global Disease Burden of African Trypanosomiasis, 2015

Table 19 Prevalence and Incidence (Number) of Dengue Cases, 2015

Table 20 Reported Cases and Deaths in Ebola Outbreaks, 2007-2016

Table 21 Zika Burden, 2015-2016

Table 22 Global Addressable Market for Neglected Tropical Diseases, by Indication, Through 2021 ($ Millions)

Table 23 Global Addressable Market for Malaria, by Region, Through 2021 ($ Millions)

Table 24 Global Addressable Market for Leishmaniasis, by Region, Through 2021 ($ Millions)

Table 25 Global Addressable Market for Schistosomiasis, by Region, Through 2021 ($ Millions)

Table 26 Global Addressable Market for Lymphatic Filariasis, by Region, Through 2021 ($ Millions)

Table 27 Global Addressable Market for Chagas Disease, by Geography, Through 2021 ($ Millions)

Table 28 Global Addressable Market for Dengue, by Region, Through 2021 ($ Millions)

Table 29 Global Addressable Market for Zika, by Region, Through 2021 ($ Millions)

Table 30 Drug Donation Commitments, by WHO

Table 31 Malaria Development Pipeline and Recent Launches

Table 32 Leishmaniasis Development Pipeline and Recent Launches

Table 33 Schistosomiasis Development Pipeline and Recent Launches

Table 34 Lymphatic Filariasis Development Pipeline and Recent Launches

Table 35 Chagas Disease Development Pipeline and Recent Launches

Table 36 African Trypanosomiasis Development Pipeline and Recent Launches

Table 37 Dengue Development Pipeline and Recent Launches

Table 38 Ebola Development Pipeline and Recent Launches

Table 39 Zika Development Pipeline and Recent Launches

Table 40 Number of Patent Applications, Malaria, by Assignee

Table 41 Number of Patent Applications, Malaria, by Year, 2010-2015

Table 42 Number of Patent Applications, Malaria, by Country

Table 43 Number of Patent Applications, Malaria, by Type

Table 44 Number of Patent Applications, Leishmaniasis, by Assignee

Table 45 Number of Patent Applications, Leishmaniasis, by Year, 2010-2015

Table 46 Number of Patent Applications, Leishmaniasis, by Country

Table 47 Number of Patent Applications, Leishmaniasis, by Type

Table 48 Number of Patent Applications, Schistosomiasis, by Assignee

Table 49 Number of Patent Applications, Schistosomiasis, by Year, 2010-2015

Table 50 Number of Patent Applications, Schistosomiasis, by Country

Table 51 Number of Patent Applications, Schistosomiasis, by Type

Table 52 Number of Patent Applications, Lymphatic Filariasis, by Assignee

Table 53 Number of Patent Applications, Lymphatic Filariasis, by Year, 2010-2015

Table 54 Number of Patent Applications, Lymphatic Filariasis, by Country

Table 55 Number of Patent Applications, Lymphatic Filariasis, by Type

Table 56 Number of Patent Applications, Chagas Disease, by Assignee

Table 57 Number of Patent Applications, Chagas Disease, by Year, 2010-2015

Table 58 Number of Patent Applications, Chagas Disease, by Country

Table 59 Number of Patent Applications, Chagas Disease, by Type

Table 60 Number of Patent Applications, African Trypanosomiasis, by Assignee

Table 61 Number of Patent Applications, African Trypanosomiasis, by Year, 2010-2015

Table 62 Number of Patent Applications, African Trypanosomiasis, by Country

Table 63 Number of Patent Applications, African Trypanosomiasis, by Type

Table 64 Number of Patent Applications, Dengue, by Assignee

Table 65 Number of Patent Applications, Dengue, by Year, 2010-2015

Table 66 Number of Patent Applications, Dengue, by Country

Table 67 Number of Patent Applications, Dengue, by Type

Table 68 Number of Patent Applications, Ebola, by Assignee

Table 69 Number of Patent Applications, Ebola, by Year, 2010-2016

Table 70 Number of Patent Applications, Ebola, by Country

Table 71 Number of Patent Applications, Ebola, by Type

Table 72 Number of Patent Applications, Zika, by Assignee

Table 73 Number of Patent Applications, Zika, by Year, 2010-2016

Table 74 Number of Patent Applications, Zika, by Country

Table 75 Number of Patent Applications, Zika, by Type

Table 76 Abbreviations Used in Neglected Tropical Diseases Landscape

Table 77 Glossary of Terms Used in Neglected Tropical Diseases Landscape

Table 78 Report Sources

List of Figures

Summary Figure: Global Market for Neglected Tropical Diseases, by Indication, 2015-2021 ($ Millions)

Figure 1 Global Number of Malaria Caused Deaths, 2011-2015

Figure 2 Global Number of Leishmaniasis Caused Deaths, 2011-2015

Figure 3 Global Leishmaniasis Years of Life Lost*, 2011-2015

Figure 4 Global Number of Schistosomiasis Caused Deaths, 2011-2015

Figure 5 Global Schistosomiasis Years of Life Lost*, 2011-2015

Figure 6 Number of Lymphatic Filariasis Endemic Countries, by Region

Figure 7 Number of Chagas Disease Caused Deaths, 2011-2015

Figure 8 Global Chagas Disease Years of Life Lost*, 2011-2015

Figure 9 Number of Cases of African Trypanosomiasis, T.b. gambiense, 2011-2015

Figure 10 Number of Cases of African Trypanosomiasis, T.b. rhodesiense, 2011-2015

Figure 11 Global Number of African Trypanosomiasis Caused Deaths, 2011-2015

Figure 12 Global African Trypanosomiasis Years of Life Lost*, 2011-2015

Figure 13 Average Annual Number of Dengue Fever Cases, 1960-2007

Figure 14 Number of Cases in American Region, 2012-2016

Figure 15 Incidence Rate (per 100,000 Inhabitants) in American Region, 2012-2016

Figure 16 Global Number of Dengue Caused Deaths, 2011-2015

Figure 17 Global Dengue Caused Years of Life Lost*, 2011-2015

Figure 18 Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number of Cases, March 2014-February 2016

Figure 19 Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number of Deaths, March 2014-February 2016

Figure 20 Number of Countries (Y) with Number of Confirmed Zika Cases (X), by American Region, 2015-2016

Figure 21 Global Addressable Market for Neglected Tropical Diseases, by Indication, 2015-2021 ($ Millions)

Figure 22 Global Market for Malaria, by Region, 2014-2021 ($ Millions)

Figure 23 Global Market for Leishmaniasis, by Region, 2014-2021 ($ Millions)

Figure 24 Global Market for Schistosomiasis, by Region, 2014-2021 ($ Millions)

Figure 25 Global Market for Lymphatic Filariasis, by Region, 2014-2021 ($ Millions)

Figure 26 Global Market for Chagas Disease, by Geography, 2014-2021 ($ Millions)

Figure 27 Global Market for Dengue, by Region, 2014-2021 ($ Millions)

Figure 28 Global Market for Zika, by Region, 2014-2021 ($ Millions)

Figure 29 Clinical Trials in Malaria, by Intervention Type, January 2005-September 2016 (%)

Figure 30 Top 20 Sponsors/Collaborators, by Clinical Trials in Malaria, January 2005-September 2016 91

Figure 31 Clinical Trials in Leishmaniasis, by Intervention Type, January 2005-September 2016 (%)

Figure 32 Key Sponsors/Collaborators, Clinical Trials in Leishmaniasis, January 2005-September 2016 94

Figure 33 Clinical Trials in Schistosomiasis, by Intervention Type, January 2005-September 2016 (%)

Figure 34 Key Sponsors/Collaborators, Clinical Trials in Lymphatic Filariasis, January 2005-September 2016

Figure 35 Clinical Trials in Chagas Disease, by Intervention Type, January 2005-September 2016 (%)

Figure 36 Key Sponsors/Collaborators, Clinical Trials in Chagas Disease, January 2005-September 2016

Figure 37 Clinical Trials in Dengue, by Intervention Type, January 2005-September 2016 (%)

Figure 38 Key Sponsors/Collaborators, Clinical Trials in Dengue, January 2005-September 2016

Figure 39 Clinical Trials in Ebola, by Intervention Type, January 2005-September 2016 (%)

Figure 40 Key Sponsors/Collaborators, Clinical Trials in Ebola, January 2005-September 2016

Figure 41 Key Sponsors/Collaborators, Clinical Trials in Zika, January 2005-September 2016

Figure 42 Patent Share for Treatment and Preventive Medicine in Malaria, by Year (%)

Figure 43 Patent Share for Treatment and Preventive Medicine in Malaria, US and non-US (%)

Figure 44 Patent Share for Treatment and Preventive Medicine in Leishmaniasis, by Year (%)

Figure 45 Patent Share for Leishmaniasis, US and non-US (%)

Figure 46 Patent Share for Treatment and Preventive Medicine in Schistosomiasis, by Year (%)

Figure 47 Patent Share for Schistosomiasis, U.S. and non-U.S. (%)

Figure 48 Patent Share for Treatment and Preventive Medicine in Lymphatic Filariasis, by Year (%)

Figure 49 Patent Share for Lymphatic Filariasis, U.S. and non-U.S. (%)

Figure 50 Patent Share for Treatment and Preventive Medicine in Chagas Disease, by Year (%)

Figure 51 Patent Share for Chagas Disease, by U.S. and non-U.S. (%)

Figure 52 Patent Share for Treatment and Preventive Medicine in African Trypanosomiasis, by Year (%)

Figure 53 Patent Share for African Trypanosomiasis, US and non-US (%)

Figure 54 Patent Share for Treatment and Preventive Medicine in Dengue, by Year (%)

Figure 55 Patent Share for Dengue, U.S. and non-U.S. (%)

Figure 56 Patent Share for Treatment and Preventive Medicine in Ebola, by Year (%)

Figure 57 Patent Share for Ebola, U.S. and non-U.S. (%)

Figure 58 Patent Share for Treatment and Preventive Medicine in Zika, by Year (%)

Figure 59 Patent Share for Zika, U.S. and Non-U.S. (%)

Figure 60 DNDi – Research Portfolio, by Phase of Development (%)

Figure 61 DNDi – Research Portfolio, by Indication (%)

Figure 62 GlaxoSmithKline – Research Portfolio, by Phase of Development (%)

Figure 63 GlaxoSmithKline – Research Portfolio, by Indication (%)

Figure 64 MMV – Research Portfolio, by Phase of Development

Figure 65 MMV – Research Portfolio, by Partner (%)

Global Markets for Neglected Tropical Disease Treatments

The global market for neglected tropical diseases should reach $2.6 billion by 2021 from $1.4 billion in 2016 at a compound annual growth rate (CAGR) of 14.1%, from 2016 to 2021.

Report Includes
An overview of the global markets for tropical disease treatments.
Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
A look at the total addressable market, an indication of the number of people affected, and the current shares of key marketed therapies.
Representations of market shares by geography, company, and future outlook.
Insight on some of the newer drug candidates, clinical trials, and their end points.
Analyses of factors such as increases in resistance of vectors to common insecticides, increases in rapid diagnostic techniques, and no established treatment for newer conditions like Zika.
Profiles of major players in the industry.

Report Scope
The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of nonbranded generics.

Products used for diagnosis as well as PCR techniques, kits and testing facilities are also excluded from the report.

BCC Research has categorized the markets based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific. These cover all the WHO participating countries which are described in detail in the subsequent section.